Blocking lymphotoxin in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, reduces disease symptoms, which is accompanied with lower levels of the chemokine CXCL13 (92). This evidence concerns the gene CXCL13 and myeloid sarcoma.